Absci (ABSI) Depreciation & Amortization (CF) (2020 - 2026)
Absci's (ABSI) quarterly Depreciation & Amortization (CF) came in at $2.7 million in Q1 2026, down 11.2% year-on-year from $3.1 million in Q1 2025, and down 3.54% quarter-over-quarter from $2.8 million in Q4 2025.
Absci (ABSI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Absci has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $2.7 million for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $2.7 million, down 11.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 million (down 12.63% YoY), and the FY2025 annual result was $11.7 million, down 12.3% from the prior year.
- Depreciation & Amortization (CF) came in at $2.7 million for Q1 2026 at Absci, down from $2.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.6 million in Q4 2022 to a low of $2.7 million in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $3.4 million (2024), against an average of $3.2 million.
- Across the five-year window, Depreciation & Amortization (CF) jumped 510.5% in 2022 and decreased 15.29% in 2025, its largest moves.
- Absci's Depreciation & Amortization (CF) stood at $3.6 million in 2022, then retreated by 2.84% to $3.5 million in 2023, then decreased by 7.18% to $3.2 million in 2024, then fell by 12.55% to $2.8 million in 2025, then dropped by 3.54% to $2.7 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.73 Mn |
| Mar 31, 2026 | 2.73 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Dec 31, 2025 | 2.83 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Mar 31, 2025 | 3.07 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Jun 30, 2024 | 3.38 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | 3.48 Mn |
| Dec 31, 2023 | 3.48 Mn |